Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

46.75
+1.914.26%
Post-market: 46.870.1200+0.26%18:56 EDT
Volume:4.08M
Turnover:190.12M
Market Cap:7.77B
PE:-13.43
High:47.42
Open:46.68
Low:45.75
Close:44.84
52wk High:86.74
52wk Low:44.66
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.79
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:17.67
PE(LYR):-19.63

Loading ...

Ionis Says Phase 3 Eplontersen Trial in Attr-cm Misses Primary Endpoint

Reuters
·
Jul 09

Update on Cardio-ttransform Phase 3 Trial of Eplontersen in Adults with Transthyretin-mediated Amyloid Cardiomyopathy

THOMSON REUTERS
·
Jul 09

Ionis Pharmaceuticals - Cardio-ttransform Phase 3 Trial for Eplontersen Misses Primary Endpoint up to Week 140

THOMSON REUTERS
·
Jul 09

Ionis Director Joseph Klein III Disposes of $910,231.42 in Common Shares

Reuters
·
Jul 07

Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone

Simply Wall St.
·
Jul 07

Ionis Completes Enrollment in Pivotal Phase 3 Reveal Cohort for Angelman Drug Obudanersen

Reuters
·
Jul 06

Ionis Pharmaceuticals - to Initiate Phase 3 Champion Study of Obudanersen Before End of 2026

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Topline Data from Reveal Study Expected in Second Half of 2027

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Adult Cohort Expected to Complete Enrollment in Q3 2026

THOMSON REUTERS
·
Jul 06

Ionis Completes Enrollment in Pivotal Cohort of the Phase 3 Reveal Study Evaluating Obudanersen in Angelman Syndrome

THOMSON REUTERS
·
Jul 06

Ionis EVP, Chief Clinical Development Officer Eugene Schneider Disposes of 26,000 Shares for $2.11 Million

Reuters
·
Jul 01

Ionis EVP Research Eric Swayze Sells 10,602 Shares for $839,082.60

Reuters
·
Jun 27

Movement Alert|Ionis Pharmaceuticals Rises 5.32% in Regular Trading, Zilganersen Global Commercialization Accelerates via Recordati Licensing Deal

Market Focus
·
Jun 26

Ionis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 25

Ionis Licenses Alexander Disease Drug Zilganersen to Recordati Outside US for $30 Million Upfront

Reuters
·
Jun 25

Ionis Pharmaceuticals - Plans Independent U.S. Launch of Zilganersen; FDA Pdufa Date Set for September 22

THOMSON REUTERS
·
Jun 25

Ionis Announces License Agreement with Recordati for Zilganersen in Alexander Disease (axd) in All Countries Outside the U.S.

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - to Retain U.S. Commercial Rights and Lead Global Development of Zilganersen

THOMSON REUTERS
·
Jun 25